new glp-1 drugs Decoding Weight Loss Medications GLP-1 Drug Pipeline 2026 |

One of these patients had a substantial amount of food discovered in the stomach during endoscopy

Am J Pathol (2020) 190(2):40011

This was not only because of the impact of GLP-1 on obesity but also because of their ability to help with so many other conditions

Medications that can enhance the activity of insulin (so-called incretin mimetics) can help to overcome insulin resistance caused by SGAs (and potentially by other psychotropic medications) and essentially lead to weight loss through enhanced fuel efficiency. Metformin, typically dosed up to 1,000 mg twice daily with meals, has increasingly become recognized as a first-line strategy to attenuate weight gain and glycemic dysregulation from SGAs via its ability to reduce insulin resistance

Maintaining weight loss in the long term could actually slow down or even reverse obesity-related issues